Clinical trials: Myeloma, Plasma-Cell
Prostate Cancer, Breast Cancer
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
This pilot clinical trial studies how well using the internet to collect symptoms and the ability to carry out daily activities works in patients with enrolled on Cancer and Leukemia Group B (CALGB) studies.
- Conditions
- Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer
- Trial name
- NCT00417040
- Testing
- internet-based intervention, assessment of therapy complications, Questionnaire Administration
- Where
- 95 sites in United States
- Volunteers
- 325 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Newly Diagnosed Multiple Myeloma
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
Multiple myeloma (MM) is a malignant disease of the BM characterized by clonal expansion of plasma cells. Current guidelines recommend that newly diagnosed transplant-eligible patients with multiple myeloma (NDMMTE) shall undergo…
- Trial name
- ELIAS (NCT05665140)
- Testing
- Isatuximab, Lenalidomide, Bortezomib
- Where
- 6 sites in Germany
- Volunteers
- 100 people
- Sponsor
- University Hopsital Schleswig Holstein Campus Lübeck
Multiple Myeloma
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
Evaluation of myeloma disease burden is currently suboptimal. This limits treatment planning and evaluation of residual disease following treatment.
- Trial name
- NCT04814615
- Testing
- 89Zr-daratumumab PET/CT
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
MS-275 in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of MS-275 in treating patients who have hematologic cancer.
- Conditions
- Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00015925
- Testing
- entinostat
- Where
- 2 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Myeloma Multiple
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
This study is being done to answer the following question: Can the addition of daratumumab-hyaluronidase to the usual treatment of bortezomib and dexamethasone improve kidney function in patients who are newly diagnosed with…
- Trial name
- NCT07085728
- Testing
- Cyclophosphamide, Bortezomib (VELCADE), Dexamethasone
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Eastern Cooperative Oncology Group
Multiple Myeloma
Monitoring of Deep of Response During Lenalidomide Maintenance in MM Patients Achieving at Least Very Good Partial Response (MRD)
This is an italian multicenter study to determine whether maintenance treatment with Lenalidomide-based regimen significantly increases the rate of molecular remission in patients achieving at least a VGPR after therapy with new…
- Trial name
- MRD (NCT03433365)
- Testing
- MRD analysis
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Fondazione EMN Italy Onlus
Leukemia, Lymphoma
Blood Samples to Identify Biomarkers of Busulfan
Specific Aim 1: To determine whether endogenous metabolomics-based biomarkers obtained before IV BU administration can predict IV BU clearance. Specific Aim 2: To characterize IV BU metabolism by metabolomics.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Immunodeficiency
- Trial name
- NCT02291965
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma, Lymphoma
Lapelga vs Gastrofil
This study is examining one-time injection of biosimilar pegfilgrastim compared with multiple injection biosimilar filgrastim post autologous hematopoietic stem cell transplantation.
- Conditions
- Multiple Myeloma, Lymphoma, Engagement, Patient, Febrile Neutropenia
- Trial name
- NCT06116734
- Testing
- Grastofil®, Lapelga
- Volunteers
- 74 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Multiple Myeloma and Plasma Cell Neoplasm
Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
RATIONALE: Drugs such as melphalan, thalidomide, and dexamethasone may be effective in treating patients with primary systemic amyloidosis.
- Trial name
- NCT00089167
- Testing
- filgrastim, dexamethasone, melphalan
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myelodysplastic Syndromes, Leukemia Myeloid Acute
Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies
The elderly comprise the most prevalent population in oncology practice. The available evidence suggests that old patients are undertreated patients, mainly because of their advanced age, regardless of whether they are highly…
- Conditions
- Myelodysplastic Syndromes, Leukemia Myeloid Acute, Multiple Myeloma, Leuklemia, Lymphocytic, Chronic
- Trial name
- GAH (NCT02164071)
- Testing
- Geriatric Assessment of Health Status Scale administration
- Where
- 22 sites in Spain
- Volunteers
- 363 people
- Sponsor
- Celgene
Plasma Cell Myeloma
Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant
This phase II trial studies how well pembrolizumab, lenalidomide, and dexamethasone work in treating patients with newly diagnosed multiple myeloma that are eligible for stem cell transplant.
- Trial name
- NCT02880228
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of tumor cells by stopping blood flow to the tumor.
- Trial name
- NCT00005834
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 93 sites in United States
- Volunteers
- 19 people
- Sponsor
- SWOG Cancer Research Network
Bone Metastases, Lymphoma
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
Nationally, the opioid crisis has become a major epidemic with increasing mortality rates each year. Orthopedic surgeons routinely prescribe narcotics instead of NSAIDs for post-op pain control because of risk of delayed healing…
- Conditions
- Bone Metastases, Lymphoma, Multiple Myeloma, Opioid Use
- Trial name
- NCT03823534
- Testing
- Ketorolac, Normal saline, Acetaminophen
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- St. Louis University
Multiple Myeloma
Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone
The purpose of this study is to assess the safety and tolerability of Elotuzumab when given in combination with Lenalidomide and low-dose Dexamethasone in subjects with relapsed or refractory multiple myeloma (MM) in Japan.
- Trial name
- NCT01241292
- Testing
- BMS-901608 (Elotuzumab) 10 mg, BMS-901608 (Elotuzumab) 20 mg
- Where
- 3 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment
The combination lenalidomide plus low-dose dexamethasone (Rd) is an active treatment for Multiple Myeloma (MM) patients, both at diagnosis and at relapse.
- Trial name
- PO-3887 (NCT03440411)
- Testing
- Pomalidomide, Cyclophosphamide, Dexamethasone
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- Fondazione EMN Italy Onlus
Multiple Myeloma
Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)
The primary purpose of this clinical study is to determine the recommended clinical doses of vorinostat (MK-0683) and bortezomib administered in combination to participants with relapsed and/or refractory multiple myeloma (MM).
- Trial name
- NCT00858234
- Testing
- Vorinostat, Bortezomib
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients
The purpose of this study is to determine whether the association of Thalidomide to Melphalan and Prednisone is effective in the treatment of newly diagnosed elderly multiple myeloma.
- Trial name
- NCT00232934
- Testing
- Thalidomide
- Where
- 13 sites in Italy
- Volunteers
- 400 people
- Sponsor
- Gruppo Italiano per lo Studio del Mieloma Multiplo
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
This clinical trial tests whether a geriatric optimization plan (GO!) works to improve survival in patients over 60 with a hematologic malignancy or bone marrow failure syndrome eligible for allogeneic hematopoietic cell…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT05972577
- Testing
- Health Promotion and Education, Medical Device Usage and Evaluation, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Relapsed and/or Refractory Multiple Myeloma
A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics (PK) of ixazomib alone or in combination with lenalidomide and dexamethasone (Rd), and antitumor activity of ixazomib in participants with RRMM.
- Trial name
- NCT04272775
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Volunteers
- 14 people
- Sponsor
- Takeda
Patient Non-adherence
Adherence to Lenalidomide Treatment in Multiple Myeloma - Prevalence, Characteristics and Clinical Significance
we intend to evaluate the association between non-adherence to Lenalidomide in Multiple Myeloma (MM) patients and overall response rates and time to progression (TTP).
- Trial name
- NCT02733224
- Volunteers
- 80 people
- Sponsor
- Rabin Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.